Theranostics Market Size to Hit USD 14.45 Billion by 2033

Theranostics Market Size, Share, Trends, By Product Type (Radiopharmaceuticals – Lu-177 Based, Ra-223 Based, I-131 Based, Sm-153 Based, Ac-225 Based; Diagnostic Imaging – PET/CT Imaging, SPECT Imaging, MRI; IVD/Biomarker Screening; Software & Services), By Technology (Positron Emission Tomography, Single Photon Emission Computed Tomography, Magnetic Resonance Imaging, Others), By Application (Oncology – Prostate Cancer, Thyroid Cancer, Neuroendocrine Tumors, Bone Metastasis, Other Cancers; Neurology; Cardiology; Infectious Diseases; Others), By End User (Hospitals & Cancer Treatment Centers, Diagnostic Imaging Centers, Research & Academic Institutes, Others), By Distribution Channel (Direct Sales, Distributors), By Region (North America – U.S., Canada, Mexico; Europe – U.K., Germany, France, Italy, Rest of Europe; Asia Pacific – China, India, Japan, South Korea, Australia, Rest of Asia Pacific; Latin America – Brazil, Argentina, Rest of Latin America; Middle East & Africa – UAE, Saudi Arabia, Rest of MEA), and Market Forecast, 2026 – 2033

  • Published: Jun, 2026
  • Report ID: 1104
  • Pages: 180+
  • Format: PDF / Excel.

This report contains the Latest Market Figures, Statistics, and Data.

Get a Sample
logo

Theranostics Market Size to Hit USD 14.45 Billion by 2033

(An Updated Version is Available)

1. Preface

  • 1.1 Report Description and Scope

  • 1.2 Research Objectives

  • 1.3 Key Questions Answered in This Report

  • 1.4 Intended Audience

  • 1.5 Currency and Pricing Conventions Used

2. Executive Summary

  • 2.1 Global Theranostics Market Snapshot

  • 2.2 Key Findings and Highlights

  • 2.3 Market Attractiveness Analysis by Segment

  • 2.4 Precision Medicine and Nuclear Medicine Macro Trends

  • 2.5 Analyst Recommendations

3. Market Introduction

  • 3.1 Definition and Scope of Theranostics

  • 3.1.1 Integration of Targeted Diagnostics and Therapeutics in Precision Medicine

  • 3.1.2 Theranostic Pairs: Gallium-68 (Diagnostic) + Lutetium-177 (Therapeutic)

  • 3.1.3 Distinction Between Radiopharmaceutical Theranostics, Companion Diagnostics, and Nanotheranostics

  • 3.2 Historical Evolution of Theranostics: From Radioiodine Thyroid Treatment to PSMA-Targeted Therapy

  • 3.3 Key Theranostic Paradigms

  • 3.3.1 PSMA-Based Theranostics for Prostate Cancer (68Ga-PSMA-11 + 177Lu-PSMA-617)

  • 3.3.2 SSTR-Based Theranostics for Neuroendocrine Tumors (68Ga-DOTATATE + 177Lu-DOTATATE / Lutathera)

  • 3.3.3 FAP-Based Radionuclides for Pan-Tumor Applications

  • 3.3.4 HER2-Targeted Theranostic Pairs for Breast and GI Cancers

  • 3.3.5 CXCR4 and Terbium Radioisotope Theranostics (Emerging)

  • 3.4 Theranostic Isotopes: Alpha vs. Beta vs. Auger Emitters

  • 3.4.1 Beta Emitters: Lu-177, Y-90, I-131 (Current Clinical Workhorses)

  • 3.4.2 Alpha Emitters: Ac-225, Pb-212, Ra-223, Bi-213 (Fastest Growing)

  • 3.4.3 Auger Electron Emitters: In-111, I-125 (Research Stage)

  • 3.5 Regulatory Framework

  • 3.5.1 U.S. FDA Approvals: Lutathera (2018), Pluvicto/177Lu-PSMA-617 (2022), Gozellix/Telix (2025)

  • 3.5.2 EMA Guidelines for Radiopharmaceutical Theranostic Products

  • 3.5.3 China NMPA Mid- and Long-Term Development Plan for Medical Isotopes (2021–2035)

  • 3.5.4 Japan PMDA Framework for Theranostic Agent Approvals

  • 3.6 Value Chain Analysis

  • 3.6.1 Radioisotope Production: Nuclear Reactors (Ac-225, Lu-177), Cyclotrons (Ga-68, Cu-64), Linear Accelerators (Tb-149)

  • 3.6.2 Radiolabeling and Conjugation Chemistry

  • 3.6.3 Quality Control, GMP Manufacturing, and Regulatory Filing

  • 3.6.4 Cold-Chain Logistics and Short-Half-Life Isotope Distribution

  • 3.6.5 Hospital Radiopharmacy, Nuclear Medicine Departments, and Patient Administration

  • 3.7 Industry Ecosystem Map (Isotope Producers, Pharma Companies, Imaging Equipment Makers, CDMOs, Hospital Networks)

4. Research Methodology

  • 4.1 Research Design and Framework

  • 4.2 Primary and Secondary Data Sources

  • 4.3 Data Triangulation and Validation Approach

  • 4.4 Market Size Estimation and Forecasting Methodology

  • 4.5 Assumptions and Limitations

  • 4.6 List of Abbreviations

5. Market Dynamics

  • 5.1 Market Drivers

  • 5.1.1 Surging Global Cancer Burden — Rising Incidence of Prostate, Neuroendocrine, Breast, and Lung Cancers Driving PSMA and SSTR Theranostic Demand

  • 5.1.2 Growing FDA, EMA, and NMPA Regulatory Momentum — Accelerated Approvals, Breakthrough Therapy Designations, and Fast-Track Pathways for Theranostic Agents

  • 5.1.3 Increasing Adoption of Precision Oncology and Personalized Medicine Driven by Companion Diagnostics Integration

  • 5.1.4 Technological Advancements in Molecular Imaging: Hybrid PET/CT, PET/MRI, and SPECT/CT Systems Enhancing Diagnostic Precision

  • 5.1.5 Rapid Clinical Expansion of Alpha-Emitter Programs (Ac-225, Pb-212) for Radioresistant Cancers

  • 5.1.6 Growing Pharmaceutical Investments and Strategic M&A in Radiopharmaceutical Theranostics (Novartis-Endocyte, EliLilly-POINT Biopharma, Bristol-Myers Squibb-RayzeBio Acquisitions)

  • 5.2 Market Restraints

  • 5.2.1 High Infrastructure and Capital Expenditure: Specialized Cyclotrons, Hot Cells, Nuclear Medicine Facilities, and Trained Personnel

  • 5.2.2 Short Radioisotope Half-Lives Creating Complex Cold-Chain Logistics and Supply Chain Vulnerabilities

  • 5.2.3 Limited Availability of Key Radioisotopes — Ac-225 and Lu-177 Global Production Shortfalls

  • 5.2.4 Reimbursement Challenges and High Per-Cycle Treatment Costs for Theranostic Radiopharmaceuticals

  • 5.3 Market Opportunities

  • 5.3.1 Expanding Theranostic Targets Beyond Oncology: Cardiovascular, Neurological (Alzheimer's, Parkinson's), Infectious Diseases, and Autoimmune Disorders

  • 5.3.2 Innovation in Nanoparticle-Based Theranostics: Liposomes, Polymeric Nanoparticles, Gold Nanoparticles for Multimodal Imaging and Targeted Drug Delivery

  • 5.3.3 AI and Radiomics Integration: AI-Powered Imaging Analysis, Tumor Heterogeneity Overcoming, and Predictive Dosimetry Tools (SNMMI Global Radiopharmaceutical Trial Finder, Aug 2025)

  • 5.3.4 Domestic Radioisotope Production Initiatives: U.S. DOE National Isotope Development Center (NIDC), China Mid-and Long-Term Plan (2021–2035), EU Horizon Programs

  • 5.3.5 Emerging Theranostic CDMO Sector: PharmaLogic-TAG1 Pb-212 Partnership (Jun 2025), AtomVie-Radiopharm Ventures Lu-177 Collaboration

  • 5.4 Market Challenges

  • 5.4.1 Tumor Heterogeneity and Variable Target Expression Reducing Universal Theranostic Efficacy

  • 5.4.2 Complexity of Radiation Safety Regulations and Personnel Training Requirements

  • 5.4.3 Intellectual Property and Patent Barriers in Proprietary Theranostic Pair Development

  • 5.5 Porter's Five Forces Analysis

  • 5.5.1 Threat of New Entrants

  • 5.5.2 Bargaining Power of Suppliers (Radioisotope Producers, Reactor Operators, Cyclotron Facilities)

  • 5.5.3 Bargaining Power of Buyers (Oncology Centers, Hospital Networks, Government Payers)

  • 5.5.4 Threat of Substitutes (Conventional Chemotherapy, Immunotherapy, Targeted Oral Oncologics, CAR-T)

  • 5.5.5 Competitive Rivalry Among Existing Theranostic Players

  • 5.6 PESTLE Analysis

  • 5.7 Pipeline Analysis: Theranostic Agents in Phase I, II, and III Clinical Trials (2026)

  • 5.8 Companion Diagnostics and Biomarker Landscape

  • 5.9 Reimbursement and Health Technology Assessment (HTA) Framework Analysis

  • 5.10 AI and Digital Health Impact on Theranostic Treatment Planning and Patient Selection

6. Global Theranostics Market Analysis, By Product Type

  • 6.1 Overview and Key Findings

  • 6.2 Drugs (Dominant Segment — Radiopharmaceuticals ~38% Market Share in 2024)

  • 6.2.1 Market Size and Forecast

  • 6.2.2 Radiopharmaceuticals

  • 6.2.2.1 Market Size and Forecast

  • 6.2.2.2 FDA/EMA-Approved Products: Lutathera (Lu-177 DOTATATE), Pluvicto (Lu-177 PSMA-617), Xofigo (Ra-223 Dichloride), Gozellix (Telix Pharmaceuticals, U.S. Launch Jun 2025)

  • 6.2.2.3 Investigational Alpha Emitters: 225Ac-PSMA-617, 212Pb-DOTAMTATE, 149Tb (Nuclidium, CHF 79M Raised Jun 2025)

  • 6.2.3 Chemotherapeutic Agents

  • 6.2.3.1 Market Size and Forecast

  • 6.2.3.2 Antibody-Drug Conjugates (ADCs) with Dual Diagnostic and Therapeutic Radiolabeling Potential

  • 6.2.4 Immunotherapeutics (Fastest Growing Drug Sub-Segment)

  • 6.2.4.1 Market Size and Forecast

  • 6.2.4.2 Quantum Dot-Enabled Immune Cell Labeling; Checkpoint Inhibitor Companion Diagnostics

  • 6.2.4.3 OncoACP3 — Philochem/RayzeBio Clinical-Stage PSMA-Targeting Theranostic Agent (Jun 2025)

  • 6.2.5 Targeted Small Molecules

  • 6.2.5.1 Market Size and Forecast

  • 6.2.6 Others (Peptide-Receptor Conjugates, Nanobody Radiopharmaceuticals)

  • 6.3 Imaging Agents

  • 6.3.1 Market Size and Forecast

  • 6.3.2 PET Imaging Agents (68Ga, 18F, 64Cu, 89Zr-Labeled Tracers)

  • 6.3.3 SPECT Imaging Agents (99mTc, 111In, 123I-Labeled Tracers)

  • 6.3.4 MRI Contrast Agents (Gadolinium-Based, Iron Oxide-Based Nanoparticles)

  • 6.3.5 Optical Imaging Agents (NIR Fluorescent Dyes, Quantum Dots)

  • 6.3.6 Ultrasound Contrast Agents

  • 6.3.7 Others

  • 6.4 Devices and Instruments

  • 6.4.1 Market Size and Forecast

  • 6.4.2 Imaging Systems: PET/CT, PET/MRI, SPECT/CT, Hybrid Digital PET Systems (GE HealthCare, Siemens Healthineers, Philips)

  • 6.4.3 Therapy Delivery Systems: Radiolabeling Hot Cells, Remote Handling Equipment, Infusion Systems

  • 6.4.4 Laboratory Analyzers and Kits: Companion Diagnostic Assays (Roche Diagnostics, Thermo Fisher Scientific, Illumina, QIAGEN)

  • 6.4.5 Others (Radiation Dosimetry Systems, Cyclotrons — IBA Radiopharma Solutions, ARTMS)

7. Global Theranostics Market Analysis, By Technology

  • 7.1 Overview and Key Findings

  • 7.2 Molecular Imaging (Dominant Technology Segment — ~32% Market Share in 2024)

  • 7.2.1 Market Size and Forecast

  • 7.2.2 Positron Emission Tomography (PET)

  • 7.2.2.1 Market Size and Forecast

  • 7.2.2.2 Whole-Body Imaging, Quantitative Data, Non-Invasive Disease Mapping

  • 7.2.2.3 Key Applications: Prostate Cancer Staging (PSMA-PET), NET Imaging (DOTATATE-PET), Brain Tumor Assessment

  • 7.2.3 Single Photon Emission Computed Tomography (SPECT)

  • 7.2.3.1 Market Size and Forecast

  • 7.2.4 Magnetic Resonance Imaging (MRI)

  • 7.2.4.1 Market Size and Forecast

  • 7.2.5 Computed Tomography (CT) — AI-Integrated CT Systems (GE Healthcare Aurora EV-ICD, Japan Apr 2025)

  • 7.2.6 Optical Imaging and Ultrasound

  • 7.3 Nanoparticle-Based Theranostics (Fastest Growing Technology Segment)

  • 7.3.1 Market Size and Forecast

  • 7.3.2 Liposomes — Chemotherapeutic and Radiopharmaceutical Payload Encapsulation

  • 7.3.3 Polymeric Nanoparticles — Controlled Drug Release and Tumor Penetration

  • 7.3.4 Gold Nanoparticles — Photothermal Therapy and CT/Optical Imaging Contrast

  • 7.3.5 Other Nanoparticle Platforms (Iron Oxide, Carbon Nanotubes, Silica Nanoparticles)

  • 7.3.6 Blood-Brain Barrier (BBB) Crossing for CNS Theranostic Applications

  • 7.4 Radiopharmaceuticals (as Standalone Technology)

  • 7.4.1 Market Size and Forecast

  • 7.4.2 Beta Emitters: Lu-177, Y-90, I-131

  • 7.4.3 Alpha Emitters: Ac-225, Pb-212, Ra-223

  • 7.4.4 Auger Electron Emitters: In-111, I-125

  • 7.5 Biomarker-Based Therapies

  • 7.5.1 Market Size and Forecast

  • 7.5.2 Protein Biomarkers (PSMA, SSTR2, HER2, FAP, CXCR4)

  • 7.5.3 Genetic Biomarkers (RAS Mutations, BRCA1/2, MSI Status — Illumina/Foundation Medicine Companion Dx)

  • 7.5.4 Metabolite Biomarkers (Tumor Glucose Uptake, Lipid Metabolism Markers)

  • 7.6 Others (Photodynamic Therapy, Photothermal Theranostics, Magnetothermal Therapy)

8. Global Theranostics Market Analysis, By Application

  • 8.1 Overview and Key Findings

  • 8.2 Oncology (Dominant and Fastest Growing Application — ~27% Market Share in 2024)

  • 8.2.1 Market Size and Forecast

  • 8.2.2 Prostate Cancer (Largest Sub-Segment — PSMA Theranostic Paradigm)

  • 8.2.2.1 Market Size and Forecast

  • 8.2.2.2 PSMA-PET Staging: 68Ga-PSMA-11 (Illuccix), 18F-DCFPyL (Pylarify, Lantheus)

  • 8.2.2.3 PSMA-Targeted Therapy: Pluvicto (177Lu-PSMA-617, Novartis/AAA — FDA Approved 2022)

  • 8.2.2.4 Investigational Alpha Emitters: 225Ac-PSMA-617 (BAMF Health, ITM)

  • 8.2.3 Neuroendocrine Tumors (NETs) (Fastest Growing Sub-Segment)

  • 8.2.3.1 Market Size and Forecast

  • 8.2.3.2 SSTR Theranostics: 68Ga-DOTATATE (Netspot) + Lutathera (177Lu-DOTATATE) — Gold Standard

  • 8.2.3.3 Pituitary and Pancreatic NET Management

  • 8.2.4 Breast Cancer (HER2-Targeted Theranostics, FAPI-Based Agents)

  • 8.2.4.1 Market Size and Forecast

  • 8.2.5 Lung Cancer

  • 8.2.5.1 Market Size and Forecast

  • 8.2.6 Thyroid Cancer (Radioiodine I-131: Foundational Theranostic Application)

  • 8.2.6.1 Market Size and Forecast

  • 8.2.7 Colorectal Cancer (RAS Panel Companion Diagnostics — Illumina/FDA Panitumumab)

  • 8.2.8 Others (Kidney, Liver, Brain Tumors, Hematological Malignancies)

  • 8.3 Cardiovascular Diseases

  • 8.3.1 Market Size and Forecast

  • 8.3.2 Myocardial Perfusion Imaging with SPECT/PET and Radiolabeled Peptide Therapies

  • 8.4 Neurological Disorders

  • 8.4.1 Market Size and Forecast

  • 8.4.2 Alzheimer's Disease: Amyloid and Tau PET Imaging (Florbetapir, Flortaucipir)

  • 8.4.3 Parkinson's Disease: DaT Scan SPECT and Investigational Alpha-Synuclein Theranostics

  • 8.5 Infectious Diseases

  • 8.5.1 Market Size and Forecast

  • 8.5.2 Radiolabeled Antimicrobials and Pathogen-Targeted Diagnostic-Therapeutic Combinations

  • 8.6 Autoimmune Disorders

  • 8.6.1 Market Size and Forecast

  • 8.6.2 Radiolabeled Antibodies for Inflammatory Lesion Detection and Targeted Immunotherapy

  • 8.7 Others (Rare Diseases, Bone Metastases, Pediatric Oncology)

9. Global Theranostics Market Analysis, By End User

  • 9.1 Overview and Key Findings

  • 9.2 Hospitals and Clinics (Dominant Segment — ~45% Market Share in 2024)

  • 9.2.1 Market Size and Forecast

  • 9.2.2 Multidisciplinary Tumor Board Integration and PERT-Equivalent Theranostic Programs

  • 9.2.3 Nuclear Medicine Departments: PET/CT and SPECT Imaging Infrastructure

  • 9.2.4 Siemens Healthineers–MGH Therapy Command Center Partnership (Jun 2025)

  • 9.3 Diagnostic Imaging Centers (Fastest Growing End User)

  • 9.3.1 Market Size and Forecast

  • 9.3.2 AI-Integrated PET/SPECT Imaging, Affordability, and Outpatient Convenience

  • 9.3.3 Rising Adoption of Independent Molecular Imaging Centers for Prostate and NET Cancer Staging

  • 9.4 Academic and Research Institutes

  • 9.4.1 Market Size and Forecast

  • 9.4.2 Clinical Trials for Novel Theranostic Pairs, Isotope Development, and Translational Research

  • 9.4.3 Champions Oncology Radiopharmaceutical Services Platform Launch (Jul 2025)

  • 9.5 Specialty Care Centers (Oncology Centers, Nuclear Medicine Centers, BAMF Health, Evergreen Theragnostics)

  • 9.5.1 Market Size and Forecast

  • 9.6 Others (CDMOs, Government Radiopharma Facilities, Military Medical Centers)

10. Global Theranostics Market Analysis, By Region

  • 10.1 Overview and Regional Key Findings

  • 10.2 North America (Dominant Region — ~40% Market Share in 2024)

  • 10.2.1 Market Size and Forecast

  • 10.2.2 United States

  • 10.2.2.1 Market Size and Forecast

  • 10.2.2.2 FDA Approval Leadership: Pluvicto, Lutathera, Gozellix (Jun 2025) — World's Largest Approved Theranostic Product Market

  • 10.2.2.3 Strong U.S. Nuclear Medicine Infrastructure and Rising Prostate and NET Cancer Incidence

  • 10.2.2.4 Strategic Partnerships: NorthStar Medical–YAP Therapeutics (Jan 2025), TAG1–PharmaLogic Pb-212 Partnership (Jun 2025)

  • 10.2.3 Canada

  • 10.2.3.1 Market Size and Forecast

  • 10.2.3.2 AtomVie Global Radiopharma CDMO and Radiopharm Ventures Lu-177 Collaboration (Oct 2024)

  • 10.3 Europe

  • 10.3.1 Market Size and Forecast

  • 10.3.2 Germany (European Leader — ~16% Regional Dominance; Lu-177 Production Scaling)

  • 10.3.2.1 Market Size and Forecast

  • 10.3.2.2 ITM Isotope Technologies Munich — Global Alpha/Beta Emitter Production Leader

  • 10.3.2.3 Nuclidium $99M Fundraise for Copper-Based Radiopharmaceuticals (Jun 2025)

  • 10.3.3 United Kingdom — Lemer Pax/Synapse Medical Radiation Protection Distribution Partnership (Apr 2025)

  • 10.3.4 France — Curium Pharma Headquarters and EU Production Capacity

  • 10.3.5 Italy — Bracco Imaging S.p.A. as Key European Imaging Agent Player

  • 10.3.6 Spain

  • 10.3.7 Sweden and Denmark (Nordic Clinical Trial Hub)

  • 10.3.8 Norway

  • 10.3.9 Rest of Europe

  • 10.4 Asia Pacific (Fastest Growing Region — ~19.1% CAGR)

  • 10.4.1 Market Size and Forecast

  • 10.4.2 China

  • 10.4.2.1 Market Size and Forecast

  • 10.4.2.2 NMPA Mid-and Long-Term Plan for Medical Isotopes (2021–2035): Domestic Isotope Production Investment

  • 10.4.2.3 Rising Cancer Burden Driving PSMA and NET Theranostic Adoption

  • 10.4.3 Japan (~18% CAGR — Precision Medtech Hub)

  • 10.4.3.1 Market Size and Forecast

  • 10.4.3.2 SSTR Agonist Pipeline; Nihon Medi-Physics as Domestic Radiopharma Leader

  • 10.4.3.3 Curium–PDRadiopharma Collaboration for 177Lu-PSMA-I&T in Japan (Oct 2024)

  • 10.4.4 India

  • 10.4.4.1 Market Size and Forecast

  • 10.4.4.2 Growing Nuclear Medicine Infrastructure; Aurobindo Pharma Radiopharma Expansion

  • 10.4.5 South Korea (PSMA Therapy Investment Boom)

  • 10.4.5.1 Market Size and Forecast

  • 10.4.6 Australia — Cyclotron Expansions Fueling APAC Theranostic Surge; Telix Pharmaceuticals HQ

  • 10.4.7 Thailand and ASEAN

  • 10.4.8 Rest of Asia Pacific

  • 10.5 Latin America

  • 10.5.1 Market Size and Forecast

  • 10.5.2 Brazil — ICPO Foundation and SBMN Strategic Partnership for Clinical Theranostics Centers (Jul 2025)

  • 10.5.3 Mexico

  • 10.5.4 Argentina

  • 10.5.5 Rest of Latin America

  • 10.6 Middle East and Africa

  • 10.6.1 Market Size and Forecast

  • 10.6.2 GCC Countries (UAE, Saudi Arabia, Kuwait)

  • 10.6.3 South Africa

  • 10.6.4 Egypt and Nigeria

  • 10.6.5 Rest of Middle East and Africa

11. Competitive Landscape

  • 11.1 Global Market Share Analysis by Key Players

  • 11.2 Competitive Benchmarking Matrix (Pipeline Depth, Theranostic Pair Coverage, Isotope Supply Control, Geographic Reach)

  • 11.3 Vendor Positioning Grid: Technology Innovators, Pipeline Leaders, Vertically Integrated Players, Niche Biotech

  • 11.4 Key Strategic Developments

  • 11.4.1 Major M&A Transactions (Novartis–Advanced Accelerator Applications; Eli Lilly–POINT Biopharma; Bristol-Myers Squibb–RayzeBio; AstraZeneca–Fusion Pharmaceuticals)

  • 11.4.2 New Product Launches and Regulatory Approvals (Telix Gozellix U.S. Launch Jun 2025; Medtronic Japan Aurora EV-ICD Mar 2025)

  • 11.4.3 Strategic Collaborations and CDMO Partnerships (Curium–PDRadiopharma Japan Agreement Oct 2024; NorthStar–YAP Therapeutics Jan 2025; Philochem–RayzeBio OncoACP3 Jun 2025)

  • 11.4.4 Clinical Trial Initiations and Phase Progressions (Starget DOTA-PTR-58 Phase 1b, Oct 2024; AVENTUS IDE Trial; CLEAN-PE)

  • 11.4.5 Geographic Expansions and Facility Investments

  • 11.5 Patent Landscape and IP Pipeline Analysis

  • 11.6 Market Concentration Analysis

12. Company Profiles

The final report includes a complete list of companies.

  • 12.1 Novartis AG (Advanced Accelerator Applications S.A.)

    • 12.1.1 Company Overview

    • 12.1.2 Financial Performance

    • 12.1.3 Product Portfolio

    • 12.1.4 Strategic Initiatives

    • 12.1.5 SWOT Analysis

  • 12.2 Bayer AG

  • 12.3 GE HealthCare Technologies, Inc.

  • 12.4 Siemens Healthineers AG

  • 12.5 Lantheus Holdings, Inc.

  • 12.6 Telix Pharmaceuticals Limited

  • 12.7 Curium Pharma

  • 12.8 ITM Isotope Technologies Munich SE (ITM)

  • 12.9 Cardinal Health, Inc.

  • 12.10 F. Hoffmann-La Roche Ltd. (Roche Diagnostics)

  • 12.11 Thermo Fisher Scientific Inc.

  • 12.12 Jubilant Radiopharma (Jubilant Pharmova Limited)

  • 12.13 Eckert & Ziegler SE

  • 12.14 Bracco Imaging S.p.A.

  • 12.15 NorthStar Medical Radioisotopes, LLC

13. Recent Developments and Industry News

  • 13.1 Key Product Launches and Regulatory Approvals (2024–2026)

  • 13.2 Major M&A Transactions, Funding Rounds, and Strategic Alliances

  • 13.3 R&D Breakthroughs: Alpha Emitters, Nanotheranostics, AI-Radiomics Integration

  • 13.4 Regulatory and Policy Updates: FDA, EMA, NMPA, PMDA

14. Appendix

  • 14.1 Detailed Research Methodology

  • 14.2 Theranostic Radioisotope Reference Table (Half-Life, Emission Type, Clinical Status)

  • 14.3 List of Tables and Figures

  • 14.4 List of Abbreviations

  • 14.5 Data Sources and References

  • 14.6 About the Publisher

15. Disclaimer

Enhance your decision-making capabilities with a 5 Reports-in-1
Bundle deal for - more than 40% off!

Our professional analysts will provide you with immediate assistance.